A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Trial Profile

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Rituximab (Primary) ; Utomilumab (Primary)
  • Indications Advanced breast cancer; B cell lymphoma; Bladder cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Lung cancer; Malignant melanoma; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jun 2018 Planned primary completion date changed from 1 Nov 2019 to 2 Nov 2019.
    • 29 May 2018 Planned primary completion date changed from 2 Nov 2019 to 1 Nov 2019.
    • 29 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top